To this end, we cloned and expressed in vitro the different proteoforms of p53 and p63 fused to HaloTag at its C-terminal end, and the different specific N-terminal and C-terminal peptides of each p53 and p63 proteoform fused to HaloTag at its C-terminal or N-terminal end, to analyze their seroreactivity using a cohort of 110 plasma samples from CRC patients, individuals with premalignant lesions (low- and high-grade adenomas), and healthy asymptomatic individuals -FOBT-positive and colonoscopy-negative individuals- (Figure 1 and Figure S1). Here, TP63 is linked to adenoma.